Atossa Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ATOS, updated each market day.
ATOS AI Sentiment
AI sees no strong directional signal for Atossa Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Atossa Therapeutics, Inc. Common Stock
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Sector
Exchange
Market Cap
$42,884,577
Cap Tier
Employees
14
Headquarters
SEATTLE, WA
Listed Since
Nov. 8, 2012
ATOS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ATOS Volatility
Atossa Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
